MasterCard (NYSE:MA) cites a decline in global transaction processing and currency headwinds as the reasons for slower growth in revenues in the second-half compared to what was witnessed in Q2. The warning came at an investor meet.
In a radical move, ten top pharma firms have come together to form a non-profit organization called TransCelerate BioPharma that will accelerate drug development by co-operating on research, revamp clinical trial procedures and adopt common data recording systems that should help regulators. The participating companies include AstraZeneca (NYSE:AZN), Eli Lilly (NYSE:LLY), GSK, J&J (NYSE:JNJ) and Pfizer (NYSE:PFE).
Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.